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Abstract The heterogeneous group of 3-methylglutaconic
aciduria (3-MGA-uria) syndromes includes several inborn
errors of metabolismbiochemically characterized by increased
urinary excretion of 3-methylglutaconic acid. Five distinct
types have been recognized: 3-methylglutaconic aciduria type
I is an inborn error of leucine catabolism; the additional four
types all affect mitochondrial function through different
pathomechanisms. We provide an overview of the expanding
clinical spectrum of the 3-MGA-uria types and provide the
newest insights into the underlying pathomechanisms. A
diagnostic approach to the patient with 3-MGA-uria is
presented, and we search for the connection between urinary
3-MGA excretion and mitochondrial dysfunction.
Abbreviations
3-HIVA 3-hydroxyisovaleric acid
3-MG 3-methylglutaric acid
3-MGA 3-methylglutaconic acid
3-MGA-uria 3-methylglutaconic aciduria
3-MGH 3-methylglutaconyl-CoA hydratase
ATP adenosine triphosphate
CoA coenzyme A
CM cardiomyopathy
CSF cerebrospinal fluid
DCMA syndrome dilated cardiomyopathy ataxia
syndrome
ETF electron transfer flavoproteins
FAD flavin adenine dinucleotide
GC–MS gas chromatography/mass
spectrometry
HMG-CoA 3-hydroxy-3-methylglutaryl-
coenzyme A
NADP nicotinamide adenine dinucleotide
phosphate
NADPH NADP, reduced
NMR nuclear magnetic resonance
OXPHOS oxidative phosphorylation system
SD standard deviation
SLO Smith-Lemli-Opitz syndrome
Branched-chain organic acid 3-methylglutaconic acid:
the biochemical basis
The branched-chain organic acid 3-methylglutaconic acid
(3-MGA) is an intermediate of the mitochondrial leucine
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leucine; 3-MGA, 3-methylglutaric acid (3-MG), and 3-
hydroxyisovaleric acid (3-HIVA) accumulate when the
conversion of 3-methylglutaconyl-coenzyme A (CoA) to 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) by the enzyme
3-methylglutaconyl-CoA hydratase (3-MGH, EC 4.2.1.18) is
disturbed. This is the underlying cause in 3-MGA-uria type I.
Asweshowindetailupondescribingthedifferentsubtypesof
3-MGA-uria, there is no evidence that the 3-MGA-uria types
II–V are caused by a disturbed leucine catabolism. Notably,
subtypes II–Vaffect mitochondrial function through different
pathomechanisms. But how can mitochondrial dysfunction
lead to elevated urinary excretion of 3-MGA?
In the urine of healthy individuals, 3-MGA is found
only in traces (< 20 mmol/mol creatinine). In patients
with 3-MGA-uria, concentrations can (intermittently) rise
above 1,000 mmol/mol creatinine. The urinary excretion
of 3-MGA is generally higher in type I than in the other
types (Elpeleg et al. 1994; Christodoulou et al. 1994;
Cantlay et al. 1999; Schmidt et al. 2004). Patients with 3-
MGA-uria type I excrete even higher amounts of urinary
3-MGA after a leucine-rich, or in general, a protein-rich
meal (Duran et al. 1982; Ensenauer et al. 2000). This is
not the case in patients with the other types of 3-MGA-
uria, which emphasizes that the excreted 3-MGA does not
originate from leucine degradation (Barth syndrome:
Kelley et al. 1991; Christodoulou et al. 1994;t y p eI V :
Chitayat et al. 1992; Wortmann et al. unpublished data).
Interestingly, in these patients, the excretion can be highly
variable or intermittently absent, even within 24 h,
seemingly unrelated to the clinical course or severity of
the metabolic derangement (Elpeleg et al. 1994; Cantlay et
al. 1999; Schmidt et al. 2004; Christodoulou et al. 1994;
Wortmann et al. 2009).
Patients with 3-MGA-uria type II (Barth syndrome) have
both increased 3-MGA and low cholesterol levels. There-
fore, it was speculated that some of the idiopathic
syndromes with 3-MGA-uria may be caused by defects of
sterol or isoprenoid metabolism causing overflow of
mevalonate carbon through the so-called mevalonate shunt
(Fig. 1; Kelley et al. 1991; Kelley and Kratz 1995). In this
shunt, dimethylallyl pyrophosphate is dephosphorylated in
Fig. 1 Leucine catabolism and possible shunts to cholesterol
biosynthesis. 1 Transaminase, 2 branched-chain 2-oxo-acid dehydro-
genase, 3 isovaleryl-CoA dehydrogenase, 4 3-methylcrotonyl-CoA
carboxylase, 5 3-methylglutaconyl-CoA-hydratase, 6 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) lyase, 7 HMG-CoA-
synthase, 8 HMG-CoA-reductase. PPi pyrophosphate
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acid, and then activated with CoA to form 3-
methylcrotonyl-CoA, the precursor of 3-MGA-CoA in the
regular leucine catabolic pathway (Edmond and Popjak
1974). Other links between the two pathways at the level of
higher-order isoprenoids, such as geraniol and farnesol,
have been described (Fig. 1; Edmond and Popjak 1974;
(Schroepfer 1981). Also, a direct shunt between mevalonate
and 3-methylglutaconyl-CoA was hypothesized (Fig. 1;
Edmond and Popjak 1974). This is the only “mevalonate
shunt” per se (Walsh et al. 1999). It seems that the shunt is
more active in tissue of ectodermal origin (e.g., skin,
placental tissue) than in tissue of mesodermal origin
(Edmond and Popjak 1974). Physiologic evidence that the
mevalonate shunt or a related shunt is significant in
humans, at least in renal tissue, has been provided
(Hughes-Fulford et al. 1986). More data are available for
rats, in which the liver is the main organ of mevalonate
shunting (Weinstock et al. 1984). Investigations in 35
patients with Smith-Lemli-Opitz syndrome (SLO, MIM
27400) showed a weak inverse correlation between
low plasma cholesterol, its elevated precursor 7-
dehydrocholesterol, and elevated plasma 3-MGA (Kelley
and Kratz 1995). SLO patients with very low plasma
cholesterol (< 200 μg/ml; seven of 35 patients) generally
had plasma 3-MGA levels above the + 2 standard deviation
(SD) range for age (five of seven patients; range 400–
5,000 nmol/l). The rise in cholesterol precursors (isopre-
noids), which cannot be metabolized to cholesterol in
patients with SLO, leads to overflow via the mevalonate
shunt and a consequential increase in 3-MGA (Fig. 1). The
authors also hypothesized another mechanism. Low plasma
cholesterol can induce HMG-CoA synthase, leading to
increased HMG-CoA levels and an increased flux through
the cholesterol biosynthesis pathway (Goldstein and Brown
1990). The HMG-CoA is then dehydrated to 3-MGA
through 3-MGH (Fig. 1; Kelley and Kratz 1995). The urine
of some patients also contained high amounts of 3-MGA
but no increased 3-HIVA levels, which is characteristic for
3-MGA-uria type I, suggesting that the 3-MGA does not
originate from leucine catabolism. Still, the described shunt
does not explain how mitochondrial dysfunction relates to
excessive 3-MGA excretion. Several enzymes involved in
leucine degradation as well as sterol biosynthesis are
nicotinamide adenine dinucleotide phosphate (NADP)–
NADP, reduced (NADPH) dependent. One could hypoth-
esize that oxidative phosphorylation system (OXPHOS)
dysfunction influences NADP-NADPH-dependent
enzymes, such as the 3-MGA-hydratase by a disturbed
NADP/NADPH ratio. However, excretion seems unrelated
to clinical severity or disease course. At the moment, 3-
MGA is a biochemical marker for mitochondrial dysfunc-
tion of still unknown origin.
Measuring 3-MGA by gas chromatography/mass
spectrometry (GC-MS) and one-dimensional [
1H]-NMR
spectroscopy
As part of the routine metabolic screening in our lab,
urinary organic acid analysis is performed by gas chroma-
tography/mass spectrometry (GC–MS) after extraction of
the urine sample with ethyl acetate and derivatization with
N,N-bis(trimethylsilyl)trifluoroacetamide containing 1%
trimethylchlorosilane. The concentration of 3-MGA is
quantified by comparing the signals obtained with calibra-
tion curves of the pure compound, using a CP-Sil 8 CB
column (Varian, Middelburg, The Netherlands) on a high-
performance (HP) 6890 Gas Chromatograph (Agilent,
Amstelveen, The Netherlands). For research purposes, we
additionally perform one-dimensional [
1H]-nuclear magnet-
ic resonance (NMR) spectroscopy of different body fluids
(Fig. 2; Engelke et al. 2006). Body fluid samples are
measured at 500 MHz on a Bruker DRX 500 spectrometer
with a triple-resonance inverse (TXI)
1H{
15N,
13C} probe
head equipped with X,Y,Z gradient coils.
1H spectra are
acquired as 128 transients in 32-K data points with a
spectral width of 6,002 Hz. The water (H2O) resonance is
presaturated by single-frequency irradiation during a relax-
ation delay of 10 s; a pulse width of 7 μs is used
(corresponding to a 90° excitation pulse).
3-MGA-uria type I (MIM 250950)
For a long time, 3-MGA-uria type I was thought to be a
classic organic aciduria. It is a rare autosomal recessive
disorder of leucine catabolism characterized by markedly
increased urinary excretion of 3-MGA and mildly elevated
urinary 3-MG and 3-HIVA. The underlying cause of 3-
MGA-uria type I is deficiency of 3-MGH, the enzyme that
catalyzes the fifth step of leucine catabolism, the conver-
sion of 3-methylglutaconyl-CoA to HMG-CoA (Fig. 1).
Murine 3-MGH is highly expressed in kidney, skeletal
muscle, heart, and brain and was shown to be located in the
mitochondria (Brennan et al. 1999). The activity of 3-MGH
can be determined in fibroblasts or lymphocytes by use of
an overall enzyme assay measuring three steps of leucine
degradation, from 3-methylcrotonyl-CoA to acetoacetate
(Narisawa et al. 1986; IJlst et al. 2002). 3-MGH is encoded
by the AUH gene, which was mapped to chromosome 9 and
encompasses ten exons encoding for a protein with 339
amino acids (Ijlst et al. 2002; Ly et al. 2003). The ratio of
cis and trans isoforms of 3-MGA in urine of 3-MGA-uria
type I patients is 2:1, whereas in cerebrospinal fluid (CSF),
only the cis isoform is detectable (Engelke et al. 2006). In
the other 3-MGA-uria types, the urinary cis:trans ratio is
approximately 1:1 [Fig. 2; repetitive measurements in
J Inherit Metab Dis (2012) 35:13–22 15patients with 3-MGA-uria type I (n=5), II (n=5), III (n=6),
and IV (n>80); (Wortmann et al. 2009)].
It is known that 3-methylcrotonyl-CoA carboxylase
specifically forms the trans form of 3-methylglutaconyl-
CoA (Lynen et al. 1961). The metabolic origin of cis-3-
methylglutaconyl-CoA remains as yet unknown. Spontane-
ous cis/trans interconversion may play a role. A brain-
specific isoform of 3-MGH or an enzyme converting the
trans form into the cis form, thus taking care of local
production of the cis form in the brain, may be an
explanation (Engelke et al. 2006).
3-MGA-uria was thought to present in childhood with
nonspecific symptoms such as mental retardation or
seizures. It was even speculated to be a nondisease (Gibson
et al. 1998). Recently, we reported that it is, in fact, a
slowly progressive leukoencephalopathy clinically present-
ing in adulthood (Wortmann et al. 2010). Function-
abolishing mutations were reported in seven children with
various nonspecific symptoms, such as mental retardation,
seizures, hepatopathy (Ijlst et al. 2002;L ye ta l .2003;
Illsinger et al. 2004; Matsumori et al. 2005). Recently, our
group reported the biochemical details of the first patient
with an adult onset of the disease, a Dutch woman (Engelke
et al. 2006; Wortmann et al. 2010). She presented with a
progressive bilateral visual decline and optic atrophy at the
age of 35 years. Over the following 16 years, dysarthria and
mild limb ataxia with severe gait ataxia were observed. One
additional late-presenting patient was reported with demen-
tia and spasticity by a Japanese group (Eriguchi et al.
2006). Both had a slowly progressive leukoencephalopathy.
The same clinical signs and symptoms and disease course
was observed in a third adult patient who came to our
attention (Wortmann et al. 2010). This British man first
presented at the age of 30 years with mild cerebellar ataxia
a n ds l o w l yw o r s e n e do v e r2 9y e a r s ,s h o w i n gs p a s t i c
paraparesis, nystagmus, and dementia. Magnetic resonance
imaging (MRI) of our adult patients showed extensive and
diffusively distributed white-matter lesions restricted to the
supratentorial region not affecting the cerebellum or the
corpus callosum [for MRI/MR spectrometry (MRS), see
Engelke et al. (2006)]. The Japanese patient also showed
cerebellar involvement (Eriguchi et al. 2006). This led us to
perform an MRI in a pediatric 3-MGA-uria type I patient
who was detected upon metabolic screening for recurrent
febrile seizures (in total, 15 up to age 7 years) at the age of
4 years (Illsinger et al. 2004). He is 10 years old at this
writing and has developed completely normally. His MRI
showed mild signal abnormalities in deep frontal white
matter with sparing of the U fibers. We propose that these
abnormalities represent the earliest stages of the slowly
progressive neurodegenerative disorder mainly affecting the
white matter observed in the adult patients. Metabolite
accumulation may contribute to the clinical signs and
symptoms of this disease. A toxic effect of 3-MGA on the
Fig. 2
[1H]-nuclear magnetic
resonance (NMR) spectra of
patients with 3-methylglutaconic
aciduria (3-MGA-uria) types I
and IV. One-dimensional [
1H]-
NMR spectra (500 MHz) of
urine measured at pH 2.5. The
region between 2.2. and 1.9 ppm
is shown. a 2:1 cis:trans ratio in
the urine of a patient with 3-
MGA-uria type I. b 1:1 cis:trans
ratio in the urine of a patient
with 3-MGA-uria type IV
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al. 2008). There have also been speculations about the
neurotoxicity of 3-HIVA (Duran et al. 1993). The obvious
accumulation of 3-HIVA in CSF and brain observed by
MRS in the Dutch woman may be indicative for a central
role of 3-HIVA accumulation in the natural course of brain
damage in this disease (Engelke et al. 2006). As in other
organic acidurias, accumulation of toxic metabolites may
give rise to slow-onset excitotoxicity with cellular dysfunc-
tion and eventually cell death. If the natural-course scenario
that we propose can be confirmed in a larger series of
patients, leucine-restricted diet as a therapeutic approach
from childhood onward must be reconsidered.
3-MGA-uria type II (Barth syndrome, MIM 302060)
The 3-MGA-uria type II or Barth syndrome is an X-linked
recessive cardiomyopathy with (cyclic) neutropenia, skele-
tal myopathy, and mitochondrial respiratory chain dysfunc-
tion first described in a large Dutch family some 30 years
ago (Barth et al. 1981, 1983). Ten years later, the 3-MGA-
uria and decreased plasma cholesterol were added as
consistent disease features (Kelley et al. 1991). Sudden
unexpected death in early life has been reported (Yen et al.
2008). The progression of cardiomyopathy (CM) is
variable, sometimes slowly improving over the years, but
mostly progressive and ending up at a point where heart
transplantation is the only treatment option (Christodoulou
et al. 1994; Adwani et al. 1997; Mangat et al. 2007). Cyclic
neutropenia, ranging from mild to severe, is frequently
seen; and fatal bacterial infections can occur in the neonatal
period. Neutropenia and CM can develop simultaneously or
in isolation. Onset ranges between birth and 49 years and
peaks around puberty (Barth et al. 2004). Chronic aphthous
ulceration due to Candida infections is a common sequela.
Treatment with granulocyte colony-stimulating factor (G-
CSF) seems to be successful and safe (Dale et al. 2006).
Most patients show a degree of growth deficiency with
height following the −2 SD percentile (Barth et al. 2004).
There is evidence that patients share distinct facial features
(tall and broad forehead, round face with prominent chin
and full cheeks, large ears, and deep-set eyes), which are
most evident in infancy (Hastings et al. 2009). In early
studies, normal mental functioning and intelligence is
reported. Recent studies suggest a higher incidence of
cognitive difficulties with regard to mathematics, visual
spatial tasks, and short-term memory. Language ability is
spared. In combination with the excess fatigue often seen in
these patients, this should be given special attention
(Mazzocco et al. 2007).
The excretion of 3-MGA in urine can be highly variable,
even within 24 h, and is often intermittent (Christodoulou et
al. 1994; Cantlay et al. 1999). The 3-MGA-uria is
seemingly unrelated to the clinical course or severity of
metabolic derangement. Even patients without 3-MGA-uria
have been described (Schmidt et al. 2004). Other charac-
teristic findings in the urine are increased levels of 3-MG
and 2-ethylhydracrylic acid, the latter a consequence of the
isoleucine breakdown. Neither prolonged fasting nor leucin
loading tests leads to changes in 3-MGA excretion,
suggesting an alternative source of 3-MGA in affected
patients (Kelley et al. 1991; Christodoulou et al. 1994).
Moderately decreased plasma total cholesterol, mostly
belonging to the low-density lipoprotein (LDL) pool, is a
consistent finding (Kelley et al. 1991). This led to the
hypothesis that 3-MGA results from overflow via the
mevalonate shunt (Fig. 1; Kelley et al. 1991; Kelley and
Kratz 1995). Cells from patients with Barth syndrome show
a characteristic abnormal cardiolipin profile, which is the
basis for the diagnosis (for review, see Houtkooper et al.
2009). Total cardiolipin levels are lower, especially of the
tetralineoyl subclasses, and the acyl chain composition is
shifted toward less unsaturated species with markedly
elevated monolysocardiolipin (Valianpour et al. 2002).
Cardiolipin is primarily found in the inner mitochondrial
membrane and to a lesser extent in the outer mitochondrial
membrane. Several proteins of the respiratory chain have
been reported to bind to cardiolipin or require cardiolipin
for optimal activity (as reviewed in Houtkooper and Vaz
2008). Furthermore, cardiolipin is reported to function in
the stabilization of the individual respiratory chain com-
plexes in a larger so-called supercomplex, enabling efficient
channelling of electrons through the complexes. Barth
syndrome is caused by mutations in the TAZ gene located
at Xq28, encoding the protein tafazzin, named after the
masochistic comic character from an Italian TV sport show
(Bione et al. 1996). The function of this mitochondrial
cardiolipin transacylase and its different splice variants
(129–292 amino acids long) in the remodelling of cardio-
lipin remains elusive. A role in apoptosis has been
suggested, but how this causes CM and neutropenia is
unknown (Houtkooper and Vaz 2008).
3-MGA-uria type III (Costeff syndrome, MIM 258501)
T h e3 - M G A - u r i at y p eI I I ,o rC o s t e f fs y n d r o m e ,i sa n
autosomal recessive disorder with infantile bilateral optic
atrophy, extrapyramidal signs, spasticity, ataxia, dysar-
thria, and cognitive deficit in decreasing order of
frequency. It was first described in 19 Israeli patients in
1989 (Costeff et al. 1989). The excretion of 3-MGA and
3-MG is, as in the other 3-MGA-uria types, quite variable
(Elpeleg et al. 1994). All patients of Iraqi Jewish origin are
homozygous for a splice site founder mutation in OPA3
J Inherit Metab Dis (2012) 35:13–22 17(mapped to 19q13.2-q13.3; Anikster et al. 2001). Several
patients have been reported since then, almost exclusively
of Iraqi Jewish origin, with the exception of one Turkish
Kurdish and one Indian patient harboring different
mutations (Kleta et al. 2002; Neas et al. 2005;H oe ta l .
2008). Two other OPA3 mutations result in a rare
dominant disorder (ADOAC; MIM 165300) involving
optic atrophy, cataracts, and extrapyramidal signs without
3-MGA-uria (Reynier et al. 2004; Verny et al. 2005). The
OPA3 gene was first thought to consist of two exons;
recently, it was proven to compromise three exons,
resulting in two gene transcripts—OPA3A and OPA3B
(Anikster et al. 2001; Huizing et al. 2010). Both transcripts
contain exon 1, which is spliced to exon 2 in OPA3A (179
amino acids) and exon 3 in OPA3B (180 amino acids).
OPA3A is expressed and conserved from fungi to primates,
whereas OPA3B is uniquely found in mammals. In contrast
to OPA3A, OPA3B is not identified in the proteomic
database and is considerably less frequently expressed in
wild-type cells (Huizing et al. 2010). Recently, the
prediction of a mitochondrial localization of the OPA3A
protein could be confirmed. It is an integral protein of the
mitochondrial outer membrane. The authors also reported
an integral role for OPA3A in mitochondrial fission and
apoptosis (Ryu et al. 2010). Very recently, a zebrafish
model of Costeff syndrome has been described. Herein
mitochondrial OPA3 is shown to protect the electron
transport chain against inhibitory compounds (Pei et al.
2010).
3-MGA-uria type IV (MIM 250951)
Although about 100 patients with 3-MGA-uria not being
classified as type I, II, III, or V have been described, OMIM
refers to only one case report from 1992 for 3-MGA-uria type
IV.Thiswasayoungmanwithseverepsychomotorretardation,
poor growth, subvalvular aortic stenosis, and CM. He later
developed seizures, spasticity, and sensorineural hearing loss
(Chitayat et al. 1992). Since then, the spectrum has expanded
rapidly. The underlying etiology has not been elucidated as
yet but is certainly heterogeneous (Gunay-Aygun 2005).
The majority of patients described so far presented with
CM (Holme et al. 1992; Ibel et al. 1993; Besley et al. 1995;
Ruesch et al. 1996; De Kremer et al. 2001; Morava et al.
2004; Sperl et al. 2006). A subgroup presented with a
severe early-onset phenotype with hypertrophic CM, and
the unique features of early cataract, hypotonia/develop-
mental delay, and lactic acidosis (Di Rosa et al. 2006).
Recently, the underlying genetic defect in a subgroup of
patients of Gypsy origin presenting with hypertrophic CM,
hypotonia, hepatomegaly, facial dysmorphism, and micro-
cephaly was found. Mutations in TMEM70 encoding a
mitochondrial protein proposed to be an ancillary factor
involved in the biosynthesis and assembly of adenosine
triphosphate (ATP) synthase (complex V of the respiratory
chain) cause an isolated deficiency of ATP synthase. Half
of the patients died, mostly within the first weeks of life;
survivors showed psychomotor and various degrees of
mental retardation (Holme et al. 1992; Sperl et al. 2006;
Cízková et al. 2008; Honzik et al. 2010). Interestingly, ATP
synthase deficiency has been reported twice more in
association with 3-MGA-uria. Recently, a young woman
with mild mental retardation and peripheral neuropathy was
described. She harbored a mutation in the ATP5E gene
encoding the F1 epsilon subunit of the ATP synthase. This
subunit is supposed to be involved in the incorporation of
subunit c to the rotor structure of mammalian ATP synthase
(Mayr et al. 2010). Some time ago, a girl with a syndromic
phenotype mimicking cerebrooculo-facio-skeletal syn-
drome (but without microphthalmia/cataracts) was reported.
She had hypoplastic kidneys, dysgenesis of the corpus
callosum, and progressive brain atrophy involving the basal
ganglia. She died aged 14 months after a course with
intercurrent infections and seizures. She was found to have
a mutation in the ATP12 gene, which encodes an ATP
synthase assembly factor (de Meirleir et al. 2004). How
these nuclear-encoded mitochondrial disorders involved in
ATP synthesis or ATP synthase assembly lead to 3-MGA-
uria remains elusive.
In 2006, we reported four patients with a distinct clinical
phenotype called MEGDEL association (Wortmann et al.
2006). These patients presented with neuroradiological
evidence of Leigh disease, sensorineural hearing loss,
recurrent lactic academia, severe neonatal infections, and
hypoglycemia. The 3-MGA in urine was moderately
elevated, and all patients had complex I deficiency. In the
mean time, we found three additional patients from other
countries. Genetic investigations are pending. Furthermore,
patients with mitochondrial DNA (mtDNA) depletion or
deletion syndromes, and m.3243A>G mutation, have been
described in literature (POLG1 mutations: de Vries et al.
2007; unspecified mtDNA depletion: Figarella-Branger et al.
1992; Scaglia et al. 2001; Pearson syndrome: Jakobs et al.
1991;G i b s o ne ta l .1992; Lichter-Konecki et al. 1993;
m.3243A>G: De Kremer et al. 2001). Recently, we
presented a diagnostic strategy that enabled us to elucidate
the underlying genetic defect in 11 out of 18 children with 3-
MGA type IV by delineating patient groups (encephalomyo-
pathic: SUCLA2;h e p a t o c e r e b r a l :POLG1, cardiomyopathic:
TMEM70,m y o p a t h i c :RYR1) on clinical and biochemical
grounds (for details, see Wortmann et al. 2009).
The 3-MGA-uria type IV is definitely the most intriguing
type of the 3-MGA-urias, with a rapidly broadening
spectrum. In contrast to the well-defined, distinct pheno-
types 3-MGA-uria I, II, III and V, 3-MGA-uria type IV is
18 J Inherit Metab Dis (2012) 35:13–22most frequently associated with progressive neurological
impairment, variable organ dysfunction, and biochemical
features of a dysfunctional OXPHOS. Urinary 3-MGA
seems to be a biochemical marker for mitochondrial
dysfunction.
3-MGA-uria type V (MIM 610198)
The 3-MGA-uria type V, or dilated cardiomyopathy with
ataxia (DCMA) syndrome, is a novel autosomal recessive
condition with early-onset dilated CM with conduction
Table 1 A diagnostic approach to the patient with 3-MGA-uria
Clinical feature in the patient with 3-MGA-uria Type Next diagnostic step Genetic
confirmation
b
Leukoencephalopathy I UOA: 3-MGA cis:trans isoforms (2:1), no ↑3-HIVA AUH
3-MGH activity in leucocytes/fibroblasts
Optic atrophy I UOA: 3-MGA cis:trans isoforms (2:1), no ↑3-HIVA AUH
3-MGH activity in leucocytes/fibroblasts
III + Iraqi Jewish origin: proceed to genetic testing OPA3
Ataxia/spasticity I UOA: 3-MGA cis:trans isoforms (2:1), no ↑3-HIVA AUH
3-MGH activity in leucocytes/fibroblasts
III + Optic atrophy: proceed to genetic testing OPA3
Sensorineural deafness IV OXPHOS measurements in muscle/fibroblasts
a SUCLA2
Encephalopathy (epilepsy, psychosis, depression) IV OXPHOS measurements in muscle/fibroblasts
a POLG1, SUCLA2
Cardiomyopathy (± cataracts) II Cardiolipin profile TAZ
+ Neutropenia: proceed to genetic testing
IV OXPHOS measurements in muscle/fibroblasts
a m.3243A>G
+ Gypsy origin: proceed to genetic testing TMEM70
V + Canadian-Hutterite origin: proceed to genetic testing DNAJC19
Liver failure IV OXPHOS measurements in muscle/fibroblasts
a POLG1
Typical case of Alpers syndrome: proceed to genetic
testing
Bone marrow failure, exocrine pancreas
insufficiency
IV Proceed to genetic testing mtDNA deletions
UOA urine organic acid analysis. See “Abbreviations” for other definitions
aIn case of suspicion of a mitochondrial disorder (e.g., combined with lactic acidosis, elevated alanine, clinical or biochemical signs, and symptomso f
multisystem disease)
bCurrent knowledge, the underlying genetic defect is not always known
Table 2 Genes, their translational products, and predicted function associated with 3-MGA-uria
Gene Type Protein Predicted function in No. patients
a
AUH I 3-methylglutaconyl-CoA hydratase Leucine catabolism 10
TAZ- II Tafazzin, a mitochondrial cardiolipin transacylase Cardiolipin remodelling >100
OPA3 III OPA3A and OPA3B protein Mitochondrial (mt) fisson, apoptosis >36
TMEM70 IV Transmembrane protein 70 Biosynthesis and assembly of ATP synthase 53
ATP5E IV ATP synthase, epsilon subunit Biosynthesis and assembly of ATP synthase 1
ATP12 IV ATP 12 protein Biosynthesis and assembly of ATP synthase 1
POLG1 IV Polymerase gamma mtDNA replication 3
m.3243A>G IV tRNA leucine mtDNA translation 1
mtDNA deletions IV Not applicable mtDNA replication and translation 6
mtDNA depletion IV Not applicable mtDNA replication and translation 5
SUCLA2 IV Succinate-CoA ligase Tricarboxylic acid cycle 3
RYR1 IV Ryanodine receptor Calcium channel of sarcoplasmatic reticulum 1
DNAJC19 V Translocase of inner mitochondrial membrane 14 Mitochondrial protein import 16
See “Abbreviations” for definitions
aGenetically confirmed, in association with 3-MGA-uria
J Inherit Metab Dis (2012) 35:13–22 19defects and nonprogressive cerebellar ataxia in 18 patients
of the Canadian Dariusleut Hutterite population, further
characterized by testicular dysgenesis and growth failure
(Davey et al. 2006). Affected patients consistently showed
five- to tenfold increases in both plasma and urine 3-MGA
and 3-MG. Homozygosity mapping revealed the underlying
splice-site mutation in the DNAJC19 gene. Proteins
containing a DNAJ domain are typically involved in
molecular chaperone systems. Based upon the predicted
tertiary structure of DNAJ19 it could be located in the inner
mitochondrial membrane. Because of the similarity with the
yeast Tim14 protein, a defect of protein import via the inner
mitochondrial membrane, as seen in Mohr-Tranebjaerg
syndrome, is suggested (Roesch et al. 2002).
Other causes of 3-MGA-uria
Elevated urinary excretion of 3-MGA, parallel with increased
excretion of 3-HIVA, 3-MG, 3-methylglutarylcarnitin, and 3-
hydroxy-3-methylglutaconic acid, can be found in patients
with HMG-CoA lyase deficiency (MIM 246450, Faull et al.
1976). This mitochondrial enzyme catalyses the last step of
leucine breakdown (Fig. 1) but is also required for
ketogenesis. Patients present with a Reye-like picture with
hypoketotic acidosis, metabolic acidosis, and liver failure.
The prognosis is good if no damage from the initial
presentation remains. The excretion pattern of HMG-CoA
lyase deficiency is characteristic and distinguishes it from the
other 3-MGA-uria types. Two patients with the late-onset
form of multiple acyl-CoA dehydrogenase deficiency
(MADD, or glutaric aciduria II, MIM 231680) also excreted
3-MGA (Liang et al. 2009). Deficient electron transfer from
the flavin adenine dinucleotide (FAD)-dependent dehydro-
genases to the respiratory chain due to genetic defects of
electron transfer flavoproteins (ETF) not only affects fatty
acid oxidation but also dehydrogenases involved in the
metabolism of amino acids (e.g., leucine), which could
explain the 3-MGA-uria. The diagnosis is difficult to
establish but worth elucidating, as treatment with riboflavin
or coenzyme Q10 shows dramatic improvement in some
patients.
The 3-MGA-uria can occur secondarily in patients with
SLO because of abnormal isoprenoid/cholesterol biosyn-
thesis, as well as in patients with glycogen storage disease
Ib (MIM 232220) and IX (MIM306000), where it is
speculated that an imbalance between gluconeogenesis
and de novo cholesterol synthesis result in secondarily
increased 3-MGA excretion (Kelley and Kratz 1995; Law
et al. 2003; Wortmann et al. unpublished data). These
patients may present with elevated lactate levels and
hypoglycemia. However, the clinical picture is distinct
enough to allow correct diagnosis.
In the 1990s a letter to the Lancet suggested that 3-
MGA-uria seen in pregnant mothers could be indicative for
a metabolic disorder or in general a congenital defect in the
offspring (De Koning et al. 1996). Investigations in a larger
cohort of pregnant women revealed that 3-MGA-uria is
frequently seen in healthy pregnant women (13/18 patients
reported by Walsh et al. 1997), and no correlation to an
underlying disease in the mother or child could be
established (Walsh et al. 1997). It is speculated that the 3-
MGA-uria occurs due to increased flux via the mevalonate
shunt, as this is possible in tissue of ectodermal origin such
as the placenta (Walsh et al. 1999). Interestingly, patients
with congenital adrenal hyperplasia and thereby elevated
production of sterol precursors do not show 3-MGA-uria.
The authors concluded that this is due to increased steroid
flux occurring in the adrenal cortex, which is of meso-
dermal origin and where the mevalonate shunt is not
supposed to function (Walsh et al. 1999).
Conclusion and approach to the patient
with unexplained 3-MGA-uria
In this review, we present to the reader the fascinating
spectrum of the 3-MGA-uria syndromes. 3-MGA-uria is
an important biochemical marker that should stimulate
the physician to proceed with investigations. Therefore,
we would end our review by providing an approach to
the patient with unexplained 3-MGA-uria. 3-MGA-uria
can be seen in two conditions: as a consistent feature in
the well-defined 3-MGA-uria subtypes I, II, III, V, and as
a marker for mitochondrial dysfunction. It is often
necessary to repeat (but certainly worth doing so) the
urine organic acid analysis, as the 3-MGA-uria can occur
intermittently. Table 1 gives an overview of which
diagnostic steps should be taken in patients with 3-
MGA-uria and unexplained signs and symptoms, such as
optic atrophy or CM. Table 2 provides an overview of all
known genes and their translational products that are
involved in the 3-MGA-urias.
Acknowledgements We thank our colleagues from the Nijmegen
Centre for Mitochondrial Disorders (NCMD) at the Department of
Pediatrics and the Institute for Genetic and Metabolic Disease (IGMD),
and at the Department of Laboratory Medicine in Nijmegen, especially
Jan Smeitink, Richard Rodenburg, and Bert van den Heuvel. We thank
Richard Kelley (Department of Pediatrics, Johns Hopkins University
Medical Center and Division of Metabolism, Kennedy Krieger Institute,
Baltimore, MD, USA) and Marjan Huizing (Cell Biology of Metabolic
Disorders Unit, National Human Genome Research Institute, Bethesda,
MD, USA) for their valuable contributions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
20 J Inherit Metab Dis (2012) 35:13–22References
Adwani SS, Whitehead BF, Rees PG et al (1997) Heart transplantation
for Barth syndrome. Pediatr Cardiol 18(2):143–145
Anikster Y, Kleta R, Shaag A et al (2001) Type III 3-methylglutaconic
aciduria (optic atrophy plus syndrome, or Costeff optic atrophy
syndrome): identification of the OPA3 gene and its founder
mutation in Iraqi Jews. Am J Hum Genet 69(6):1218–1224
Barth PG, Van't Veer-Korthof ET, Van Delden L et al (1981) An X-
linked mitochondrial disease affecting cardiac muscle, skeletal
muscle and neutrophil leukocytes. In: Busch HFM, Jennekens
FGI, Schotte HR (eds) Mitochondria and Muscular Diseases.
Beetsterzwaag: 161–164
Barth PG, Scholte JA, Berden JA, Van der Klei-Van Moorsel JM et al
(1983) An X-linked mitochondrial disease affecting cardiac muscle,
skeletal muscle and neutrophil leucocytes. J Neurol Sci 62:327–355
Barth PG, Valianpour F, Bowen VM et al (2004) X-linked
cardioskeletal myopathy and neutropenia (Barth syndrome): an
update. Am J Med Genet A 126A(4):349–354
Besley GT, Lendon M, Broadhead DM et al (1995) Mitochondrial
complex deficiencies in a male with cardiomyopathy and 3-
methylglutaconic aciduria. J Inherit Metab Dis 18(2):221–223
Bione S, D'Adamo P, Maestrini E et al (1996) A novel X-linked gene,
G4.5. is responsible for Barth syndrome. Nat Genet 12(4):385–389
Brennan LE, Nakagawa J, Egger D et al (1999) Characterisation and
mitochondrial localisation of AUH, an AU-specific RNA-binding
enoyl-CoA hydratase. Gene 228:85–91
Cantlay A, Shokrollahi K, Allen J et al (1999) Genetic analysis of the
G4.5 gene in families with suspected Barth syndrome. J Pediatr
135:311–315
Chitayat D, Chemke J, Gibson KM et al (1992) 3-Methylglutaconic
aciduria: a marker for as yet unspecified disorders and the relevance
of prenatal diagnosis in a ‘new’ type (‘type 4’). J Inherit Metab Dis
15:204–212
Christodoulou J, McInnes R, Jay V et al (1994) Barth syndrome:
clinical observations and genetic lnkage studies. Am J Med
Genet 50(3):255–264
Cízková A, Stránecký V, Mayr JA et al (2008) TMEM70 mutations
cause isolated ATP synthase deficiency and neonatal mitochon-
drial encephalocardiomyopathy. Nat Genet 40(11):1288–1290
Costeff H, Gadoth N, Apter N et al (1989) A familial syndrome of
infantile optic atrophy, movement disorder, and spastic paraplegia.
Neurology 39(4):595–597
Dale DC, Bolyard AA, Schwinzer BG et al (2006) The severe chronic
neutropenia international registry: 10-year follow-up report.
Support Cancer Ther 3(4):220–231
Davey KM, Parboosingh JS, McLeod DR et al (2006) Mutation of
DNAJC19, a human homologue of yeast inner mitochondrial
membrane co-chaperones, causes DCMA syndrome, a novel
autosomal recessive Barth syndrome-like condition. J Med Genet
43(5):385–393
De Koning T, Duran M, Dorland L et al (1996) Maternal 3-
methylglutaconic aciduria associated with abnormalities in
offspring. Lancet 348(9031):887–888
De Kremer RD, Paschini-Capra A, Bacman S et al (2001) Barth’s
syndrome-like disorder: a new phenotype with a maternally
inherited A3243G substitution of mitochondrial DNA (MELAS
mutation). Am J Med Genet 99(2):83–93
De Meirleir L, Seneca S, Lissens W et al (2004) Respiratory chain
complex V deficiency due to a mutation in the assembly gene
ATP12. J Med Genet 41(2):120–4
De Vries MC, Rodenburg RJ, Morava E et al (2007) Multiple
oxidative phosphorylation deficiencies in severe childhood multi-
system disorders due to polymerase gamma (POLG1) mutations.
Eur J Pediatr 166(3):229–234
Di Rosa G, Deodato F, Loupatty FJ et al (2006) Hypertrophic
cardiomyopathy, cataract, developmental delay, lactic acidosis: a
novel subtype of 3-methylglutaconic aciduria. J Inherit Metab
Dis 29(4):546–550
Duran M, Beemer FA, Tibosch AS et al (1982). Inherited 3-
methylglutaconic aciduria in two brothers–another defect of
leucine metabolism. J Pediatr 101(4):551–4
Duran M, Baumgartner ER, Suormala TM et al (1993) Cerebrospinal
fluid organic acids in Biotinidase deficiency. J Inherit Metab Dis
16:513–516
Edmond J, Popjak G (1974) Transfer of carbon atoms from
mevalonate to n-fatty acids. J Biol Chem 249(1):66–71
Elpeleg ON, Costeff H, Joseph A et al (1994) 3-Methylglutaconic
aciduria in the Iraqi-Jewish ‘optic atrophy plus’ (Costeff)
syndrome. Dev Med Child Neurol 36(2):167–172
Engelke U, Kremer B, Kluijtmans L et al (2006) NMR spectroscopic
studies on the late onset form of 3-methylglutaconic aciduria type
I and other defects in leucine metabolism. NMR Biomed 19
(2):271–278
Ensenauer R, Muller CB, Schwab KO et al (2000) 3-Methylglutaconyl-
CoA hydratase deficiency: a new patient with speech retardation as
the leading sign. J Inherit Metab Dis 23:341–344
Eriguchi M, Mizuta H, Kurohara K et al (2006) 3-methylglutaconic
aciduria type I causes leukoencephalopathy of adult onset.
Neurology 67:1895–1896
Faull K, Bolton P, Halpern B et al (1976) Patient with defect in leucine
metabolism. New Eng J Med 294:1013
Figarella-Branger D, Pellissier JF, Scheiner C et al (1992) Defects of the
mitochondrial respiratory chain complexes in three pediatric cases with
hypotonia and cardiac involvement. J Neurol Sci 108(1):105–113
Gibson KM, Bennett MJ, Mize CE et al (1992) 3-methylglutaconic
aciduria associated with Pearson syndrome and respiratory chain
defects. J Pediatr 121:940–942
Gibson KM, Wappner RS, Jooste S et al (1998) Variable clinical
presentation in three patients with 3-methylglutaconyl-coenzyme
A hydratase deficiency. J Inherit Metab Dis 21(6):631–638
Goldstein JL, Brown MS (1990) Regulation of the mevalonate
pathway. Nature 343:425–430
Gunay-Aygun M (2005) 3-methylglutaconic aciduria: a common
biochemical marker in various syndromes with diverse clinical
features. Mol Genet Metab 84:1–3
Hastings R, Steward C, Tsai-Goodman B et al (2009) Dysmorphology
of Barth syndrome. Clin Dysmorphol 18(4):185–187
Ho G, Walter J, Christodoulou J (2008) Costeff optic atrophy
syndrome: New clinical case and novel molecular findings. J
Inherit Metab Dis. Short Report #134
Holme E, Greter J, Jacobsen CE et al (1992) Mitochondrial ATP-
synthase deficiency in a child with 3-methylglutaconic aciduria.
Pediatr Res 32(6):731–735
Honzík T, Tesarová M, Mayr JA et al (2010) Mitochondrial
encephalocardio-myopathy with early neonatal onset due to
TMEM70 mutation. Arch Dis Child 95(4):296–301
Houtkooper RH, Vaz FM (2008) Cardiolipin, the heart of mitochon-
drial metabolism. Cell Mol Life Sci 65(16):2493–2506
Houtkooper RH, Turkenburg M, Poll-The BT et al (2009) The
enigmatic role of tafazzin in cardiolipin metabolism. Biochim
Biophys Acta 1788(10):2003–2014
Hughes-Fulford M, Feingold KR, Searle GL et al (1986) Role of the
kidneys in the metabolism of circulating mevalonate in humans. J
Clin Endocrinol Metab 62(6):1227–1231
Huizing M, Dorward H, Ly L et al (2010) OPA3, mutated in 3-
methylglutaconic aciduria type III, encodes two transcripts targeted
primarily to mitochondria. Mol Genet Metab 100(2):149–154
Ibel H, Endres W, Hadorn HB et al (1993) Multiple respiratory chain
abnormalities associated with hypertrophic cardiomyopathy and
3-methylglutaconic aciduria. Eur J Pediatr 152(8):665–670
J Inherit Metab Dis (2012) 35:13–22 21IJlst L, Loupatty FJ, Ruiter JP et al (2002) 3-Methylglutaconic aciduria
type I is caused by mutations in AUH. Am J Hum Genet 71
(6):1463–1466
Illsinger S, Lucke T, Zschocke J et al (2004) 3-Methylglutaconic
aciduria type I in a boy with fever-associated seizures. Pediatr
Neurol 30:213–215
Jakobs C, Danse P, Veerman A (1991) Organic aciduria in Pearson
syndrome. Eur J Pediatr 150(9):684
Kelley R, Kratz L (1995) 3-methylglutaconic Acidemia in Smith-
Lemli-Opitz syndrome. Pediatr Res 37(5):671–674
Kelley R, Cheatham J, Clark B et al (1991) X-linked dilated
cardiomyopathy with neutropenia, growth retardation, and 3-
methylglutaconic aciduria. J Pediatr 119:738–747
Kleta R, Skovby F, Christensen E et al (2002) 3-Methylglutaconic
aciduria type III in a non-Iraqi-Jewish kindred: clinical and
molecular findings. Mol Genet Metab 76(3):201–206
Law LK, Tang NL, Hui J et al (2003) 3-methyglutaconic aciduria in a
Chinese patient with glycogen storage disease Ib. J Inherit Metab
Dis 26(7):705–709
Leipnitz G, Seminotti B, Amaral AU et al (2008) Induction of oxidative
stress by the metabolites accumulating in 3-methylglutaconic
aciduria in cerebral cortex of young rats. Life Sci 82:652–662
Liang WC, Ohkuma A, Hayashi YK et al (2009) ETFDH mutations,
CoQ10 levels, and respiratory chain activities in patients with
riboflavin-responsive multipleacyl-CoAdehydrogenase deficiency.
Neuromuscul Disord 19(3):212–216
Lichter-Konecki U, Trefz F, Rötig A et al (1993) 3-methylglutaconic
aciduria in a patient with Pearson syndrome. Eur J Pediatr 152
(4):378–379
LyTB, Peters V, GibsonKMet al (2003) Mutations inthe AUH gene cause
3-methylglutaconic aciduria type I. Hum Mutat 21(4):401–407
Lynen F, Knappe J, Lorch E et al (1961) On the biochemical function
of biotin. II. Putification and mode of action of beta-methyl-
crotonyl-carboxylase. Biochem Z 335:123–167
Mangat J, Lunnon-Wood T, Rees P et al (2007) Successful cardiac
transplantation in Barth syndrome–single-centre experience of
four patients. Pediatr Transplant 11(3):327–331
Matsumori M, Shoji Y, Takahashi T et al (2005) A molecular lesion in
a Japanese patient with severe phenotype of 3-methylglutaconic
aciduria type I. Pediatr Int 47:684–686
Mayr JA, Havlícková V, Zimmermann F et al (2010) Mitochondrial
ATP synthase deficiency due to a mutation in the ATP5E gene for
the F1 {varepsilon} subunit. Hum Mol Genet 19(17):3430–3439
Mazzocco MM, Henry AE, Kelly RI (2007) Barth syndrome is
associated with a cognitive phenotype. J Dev Behav Pediatr 28
(1):22–30
Morava E, Sengers R, ter Laak H et al (2004) Congenital hypertrophic
cardiomyopathy, cataract, mitochondrial myopathy and defective
oxidative phosphorylation in two siblings with Sengers-like
syndrome. Eur J Pediatr 163(8):467–471
Narisawa K, Gibson KM, Sweetman L et al (1986) Deficiency of 3-
methylglutaconyl-coenzyme A hydratase in two siblings with 3-
methylglutaconic aciduria. J Clin Invest 77:1148–1152
Neas K, Bennetts B, Carpenter K et al (2005) OPA3 mutation
screening in patients with unexplained 3-methylglutaconic
aciduria. J Inherit Metab Dis 28(4):525–532
Pei W, Kratz LE, Bernardini I et al (2010) A model of Costeff
syndrome reveals metabolic and protective functions of mito-
chondrial OPA3. Development 137(15):2587–2596
Reynier P, Amati-Bonneau P, Verny C et al (2004) OPA3 gene
mutations responsible for autosomal dominant optic atrophy and
cataract. J Med Genet 41(9):e110
Roesch K, Curran SP, Tranebjaerg L et al (2002) Human deafness
dystonia syndrome is caused by a defect in assembly of the DDP1/
TIMM8a-TIMM13 complex. Hum Mol Genet 11(5):477–486
Ruesch S, Krakenbuhl S, Kleinle S et al (1996) Combined 3-
methylglutaconic and 3-hydroxy-3-methylglutaric aciduria with
endocardial fibroelastosis and dilatative cardiomyopathy in male
and female siblings with partial deficiency of complex II/III in
fibroblasts. Enzyme Protein 49(5–6):321–329
Ryu SW, Jeong HJ, Choi M, et al (2010) Optic atrophy 3 as a protein
of the mitochondrial outer membrane induces mitochondrial
fragmentation. Cell Mol Life Sci 67(16):2839–50
Scaglia F, Sutton VR, Bodamer OA et al (2001) Mitochondrial DNA
depletion associated with partial complex II and IV deficiencies
and 3-methylglutaconic aciduria. J Child Neurol 16(2):136–138
Schmidt MR, Birkebaek N, Gonzalez I, Sunde L (2004) Barth
syndrome without 3-methylglutaconic aciduria. Acta Paediatr
93(3):419–421
Schroepfer GJ Jr (1981) Sterol biosynthesis. Annu Rev Biochem
50:585–621
Sperl W, Jesina P, Zeman J et al (2006) Deficiency of mitochondrial
ATP synthase of nuclear genetic origin. Neuromuscul Disord
12:821–829
Valianpour F, Wanders RJA, Overmars H et al (2002) Cardiolipin
deficiency in X-linked cardioskeletal myopathy and neutropenia
(Barth syndrome, MIM 302060): a study in cultured skin
fibroblasts. J Pediat 141:729–733
Verny C, Amati-Bonneau P, Dubas F et al (2005) An OPA3 gene
mutation is responsible for the disease associatingoptic atrophy and
cataractwithextrapyramidalsigns.RevNeurol(Paris)161:451–454
Walsh R, Conway H, Roche G et al (1997) 3-Methylglutaconic
aciduria in pregnancy. Lancet 349(9054):776
Walsh R, Conway H, Roche G, Mayne PD (1999) What is the origin
of 3-methylglutaconic acid? J Inherit Metab Dis 22(3):251–255
Weinstock SB, Kopito RR, Endemann G et al (1984) The shunt
pathway of mevalonate metabolism in the isolated perfused rat
liver. J Biol Chem 259(14):8939–8944
Wortmann S, Rodenburg RJ, Huizing M et al (2006) Association of 3-
methylglutaconic aciduria with sensori-neural deafness, enceph-
alopathy, and Leigh-like syndrome (MEGDEL association) in
four patients with a disorder of the oxidative phosphorylation.
Mol Genet Metab 88(1):47–52
Wortmann SB, Rodenburg RJT, Jonckheere A et al (2009) Biochemical
and genetic analysis of 3-methylglutaconic aciduria type IV: a
diagnostic strategy. Brain 132(Pt 1):136–146
Wortmann SB, Kremer BH, Graham A et al (2010) 3-
Methylglutaconic aciduria type I redefined; a syndrome with late
onset leukoencephalopathy. Neurology [in press]
Yen TY, Hwu WL, Chien YH et al (2008) Acute metabolic
decompensation and sudden death in Barth syndrome: report of
a family and a literature review. Eur J Pediatr 167(8):941–944
22 J Inherit Metab Dis (2012) 35:13–22